Perspective Therapeutics (NYSEAMERICAN:CATX) Trading Down 2.3% - What's Next?

Key Points

• Perspective Therapeutics shares fell 2.3% on Monday, trading as low as $2.88 before ending near $2.92, with volume running well below average.
• Despite the stock weakness, analysts remain bullish: eight analysts rate CATX a Buy, with an average target price of $12.62 after HC Wainwright raised its target to $13 and Wedbush reiterated an $11 target.
• The company beat earnings expectations last quarter by posting a smaller-than-expected loss of $0.25 per share, though revenue came in below estimates and analysts still expect a full-year loss.

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) shares were down 2.3% during trading on Monday . The company traded as low as $2.88 and last traded at $2.92. 915,349 shares traded hands during mid-day trading, a decline of 60% from the average session volume of 2,297,648 shares. The stock had previously closed at $2.99.

Wall Street Analyst Weigh In

Several equities analysts have commented on CATX shares. HC Wainwright increased their price target on shares of Perspective Therapeutics from $12.00 to $13.00 and gave the company a "buy" rating in a research note on Monday, March 23rd. Wedbush restated an "outperform" rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research note on Tuesday, May 5th. Eight analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $12.62.

Perspective Therapeutics Trading Down 2.3%

The business's 50 day moving average price is $3.38 and its 200-day moving average price is $3.90.

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.04. The company had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.16 million. Perspective Therapeutics had a negative return on equity of 42.33% and a negative net margin of 17,982.69%. Research analysts predict that Perspective Therapeutics, Inc. will post -1.1 EPS for the current year.

Institutional Investors Weigh In On Perspective Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CATX. UBS Group AG lifted its stake in shares of Perspective Therapeutics by 44.5% in the fourth quarter. UBS Group AG now owns 926,331 shares of the company's stock valued at $2,547,000 after purchasing an additional 285,188 shares during the period. Avidity Partners Management LP increased its holdings in Perspective Therapeutics by 7.2% in the fourth quarter. Avidity Partners Management LP now owns 3,210,733 shares of the company's stock valued at $8,830,000 after buying an additional 216,700 shares in the last quarter. AXQ Capital LP lifted its position in shares of Perspective Therapeutics by 24.2% during the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company's stock valued at $35,000 after acquiring an additional 2,481 shares during the period. R Squared Ltd purchased a new stake in shares of Perspective Therapeutics during the 4th quarter worth approximately $44,000. Finally, Octagon Capital Advisors LP purchased a new stake in shares of Perspective Therapeutics during the 1st quarter worth approximately $3,301,000. Institutional investors and hedge funds own 54.66% of the company's stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.